Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis

• Published in: European journal of clinical microbiology & infectious diseases Vol. 40; no. 6; pp. 1169 - 1176
• Main Authors: Gatti, Milo, Raschi, Emanuel, De Ponti, Fabrizio
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2021; Springer Nature B.V
• Subjects: Adverse events; Amides; Antibiotics; Biomedical and Life Sciences; Biomedicine; Causality; Ceftazidime; Cephalosporins; Confidence intervals; Drugs; Encephalopathy; HIV; Human immunodeficiency virus; Infections; Internal Medicine; Kidneys; Medical Microbiology; Multidrug resistance; Neurotoxicity; Neutropenia; Original; Original Article; Pancreatitis; Pancytopenia; Patients; Pharmacovigilance; Qualitative analysis; Risk groups; Sepsis; Tazobactam; β Lactamase; β-Lactam antibiotics; Ceftolozane-tazobactam; Neurotoxicity; Ceftazidime-avibactam; Agranulocytosis; Safety profile

The purpose of this study is to characterize adverse events (AEs) of clinical interest reported with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients affected by severe multidrug-resistant Gram-negative infections. We queried the worldwide FDA Adverse Event Reportin...